| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Serum ceruloplasmin can predict liver fibrosis in hepatitis B virus-infected patients
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Na-Ling Kang, Jie-Min Zhang, Meng-Xin Lin, Xu-Dong Chen, Zu-Xiong Huang, Yue-Yong Zhu, Yu-Rui Liu and Da-Wu Zeng |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Science and Technology Department of Fujian Province |
2018J01164 |
| Quanzhou Science and Technology Bureau Planning Project |
2019N019S |
|
| Corresponding Author |
Da-Wu Zeng, MD, PhD, Associate Chief Physician, Doctor, Doctor, Liver Center, The First Affiliated Hospital, Fujian Medical University, No. 20 Chazhong Road, Taijiang District, Fuzhou 350005, Fujian Province, China. zengdw1980@fjmu.edu.cn |
| Key Words |
Ceruloplasmin; Liver fibrosis; Chronic hepatitis B infection; Serum alanine aminotransferase; Noninvasive model; Receiver-operating characteristic |
| Core Tip |
Chronic hepatitis B virus (HBV)-infected individuals with persistently normal serum alanine aminotransferase levels (PNALT) may develop severe liver fibrosis, which requires antiviral therapy. Following up on our previous findings, this multicenter, cross-sectional study showed that ceruloplasmin (CP) has an inverse correlation with liver fibrosis and is a promising predictive marker for liver fibrosis among HBV-infected individuals with PNALT. We developed a noninvasive model using CP, platelet, and HBsAg levels to identify the various stages of fibrosis among HBV-infected individuals with PNALT. Our model could reduce the need for liver biopsy before antiviral treatment. |
| Publish Date |
2020-07-21 13:23 |
| Citation |
Kang NL, Zhang JM, Lin MX, Chen XD, Huang ZX, Zhu YY, Liu YR, Zeng DW. Serum ceruloplasmin can predict liver fibrosis in hepatitis B virus-infected patients. World J Gastroenterol 2020; 26(27): 3952-3962 |
| URL |
https://www.wjgnet.com/1007-9327/full/v26/i27/3952.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v26.i27.3952 |
